Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Sci Rep ; 9(1): 16546, 2019 11 13.
Artículo en Inglés | MEDLINE | ID: mdl-31723225

RESUMEN

The pathogenesis of synucleinopathies, common neuropathological lesions normally associated with some human neurodegenerative disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, remains poorly understood. In animals, ingestion of the tryptamine-alkaloid-rich phalaris pastures plants causes a disorder called Phalaris staggers, a neurological syndrome reported in kangaroos. The aim of the study was to characterise the clinical and neuropathological changes associated with spontaneous cases of Phalaris staggers in kangaroos. Gross, histological, ultrastructural and Immunohistochemical studies were performed to demonstrate neuronal accumulation of neuromelanin and aggregated α-synuclein. ELISA and mass spectrometry were used to detect serum-borne α-synuclein and tryptamine alkaloids respectively. We report that neurons in the central and enteric nervous systems of affected kangaroos display extensive accumulation of neuromelanin in the perikaryon without affecting neuronal morphology. Ultrastructural studies confirmed the typical structure of neuromelanin. While we demonstrated strong staining of α-synuclein, restricted to neurons, intracytoplasmic Lewy bodies inclusions were not observed. α-synuclein aggregates levels were shown to be lower in sera of the affected kangaroos compared to unaffected herd mate kangaroos. Finally, mass spectrometry failed to detect the alkaloid toxins in the sera derived from the affected kangaroos. Our preliminary findings warrant further investigation of Phalaris staggers in kangaroos, potentially a valuable large animal model for environmentally-acquired toxic synucleinopathy.


Asunto(s)
Alcaloides/envenenamiento , Melaninas/metabolismo , Phalaris/química , Sinucleinopatías/metabolismo , Triptaminas/química , alfa-Sinucleína/metabolismo , Alcaloides/sangre , Alcaloides/química , Animales , Modelos Animales de Enfermedad , Femenino , Macropodidae , Masculino , Espectrometría de Masas , Neuronas/metabolismo , Extractos Vegetales/química , Agregado de Proteínas , Sinucleinopatías/inducido químicamente
2.
Neurotox Res ; 17(3): 203-14, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19644728

RESUMEN

A loss of synapses is characteristic of the early stages of the prion diseases. Here we modelled the synapse damage that occurs in prion diseases by measuring the amount of synaptophysin, a pre-synaptic membrane protein essential for neurotransmission, in cortical or hippocampal neurones incubated with the disease associated isoform of the prion protein (PrP(Sc)), or with the prion-derived peptide PrP82-146. The addition of PrP(Sc) or PrP82-146 caused a dose-dependent reduction in the synaptophysin content of PrP wildtype neurones indicative of synapse damage. They did not affect the synaptophysin content of PrP null neurones. The loss of synaptophysin in PrP wildtype neurones was preceded by the accumulation of PrP82-146 within synapses. Since supplements containing polyunsaturated fatty acids (PUFA) are frequently taken for their perceived health benefits including reported amelioration of neurodegenerative conditions, the effects of some common PUFA on prion-mediated synapse damage were examined. Pre-treatment of cortical or hippocampal neurones with docosahexaenoic (DHA) or eicosapentaenoic acids (EPA) protected neurones against the loss of synaptophysin induced by PrP82-146 or PrP(Sc). This effect of DHA and EPA was selective as they did not alter the loss of synaptophysin induced by a snakevenom neurotoxin. The effects of DHA and EPA were associated with a significant reduction in the amount of FITC-PrP82-146 that accumulated within synapses. Such observations raise the possibility that supplements containing PUFA may protect against the synapse damage and cognitive loss seen during the early stages of prion diseases.


Asunto(s)
Ácidos Grasos Insaturados/farmacología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Priones/metabolismo , Sinaptosomas/efectos de los fármacos , Animales , Caspasa 3/metabolismo , Células Cultivadas , Corteza Cerebral/citología , Ácidos Docosahexaenoicos/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Ácido Eicosapentaenoico/farmacología , Embrión de Mamíferos , Ensayo de Inmunoadsorción Enzimática/métodos , Regulación de la Expresión Génica/efectos de los fármacos , Hipocampo/citología , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Técnicas In Vitro , Ratones , Ratones Noqueados , Neuronas/metabolismo , Fragmentos de Péptidos/farmacología , Priones/genética , Priones/farmacología , Simvastatina/farmacología , Sinaptofisina/metabolismo , Sinaptosomas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA